HC Wainwright & Co. Initiates Coverage of Biohaven (BHVN) with …

Dec 18, 2023 · Fintel reports that on December 22, 2023, HC Wainwright & Co. initiated coverage of Biohaven with a Buy recommendation. Analyst Price Forecast Suggests 5.47% Downside. …

CouponFollow Extension

47%
OFF

HC Wainwright & Co. Initiates Coverage Of Biohaven (BHVN) With …

1 week from now

Dec 18, 2023 · Fintel reports that on December 22, 2023, HC Wainwright & Co. initiated coverage of Biohaven with a Buy recommendation. Analyst Price Forecast Suggests 5.47% Downside. …

nasdaq.com

47%
OFF

HC Wainwright & Co. Initiates Coverage Of Biohaven (BHVN) With …

1 week from now

Dec 23, 2023 · Fintel reports that on December 22, 2023, HC Wainwright & Co. initiated coverage of Biohaven with a Buy recommendation. Analyst Price Forecast Suggests 5.47% Downside. …

currentstocktrends.com

$59.00
OFF

Analysts Offer Insights On Healthcare Companies: Biohaven Ltd.

1 week from now

Sep 24, 2024 · Biohaven Ltd. (BHVN) H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Biohaven Ltd. today and set a price target of $59.00 . The company’s shares closed …

businessinsider.com

$220950.00
OFF

BHVN News Today | Why Did Biohaven Stock Go Down Today?

1 week from now

2 days ago · Biohaven Ltd. (NYSE:BHVN) Director Buys $220,950.00 in Stock. Biohaven Ltd. (NYSE:BHVN - Get Free Report) Director Gregory Bailey bought 5,000 shares of the firm's …

marketbeat.com

$18.00
OFF

Analysts Offer Insights On Healthcare Companies: Biohaven Ltd.

1 week from now

Oct 9, 2024 · In a report issued on September 27, H.C. Wainwright also maintained a Buy rating on the stock with a $18.00 price target. Read More on BHVN: Biohaven price target raised to …

businessinsider.com

$63
OFF

Buy Rating Affirmed For Biohaven Ltd. Amid Positive Clinical …

1 week from now

Apr 14, 2024 · Biohaven price target raised to $63 from $50 at H.C. Wainwright Biohaven price target raised to $55 from $35 at TD Cowen Biohaven reports Q4 non-GAAP EPS ($1.61), …

businessinsider.com

$50.00
OFF

Analysts’ Top Healthcare Picks: Legend Biotech (LEGN), Xoma …

1 week from now

Dec 22, 2023 · Biohaven Ltd. (BHVN) H.C. Wainwright analyst Douglas Tsao initiated coverage with a Buy rating on Biohaven Ltd. today and set a price target of $50.00.The company’s …

businessinsider.com

$37
OFF

BHVN - Biohaven Ltd Stock Price And Quote - FINVIZ.com

1 week from now

Mar-25-23 09:22AM. Bullish Biohaven Ltd. (NYSE:BHVN) insiders filled their treasuries with US$37m worth of stock over last year. (Simply Wall St.) Mar-23-23 04:05PM. Biohaven …

finviz.com

$50
OFF

HC Wainwright & Co. Initiates Coverage On Biohaven With Buy …

1 week from now

Dec 22, 2023 · HC Wainwright Co. analyst Douglas Tsao initiates coverage on Biohaven (NYSE:BHVN) with a Buy rating and announces Price Target of $50.

sahmcapital.com

47%
OFF

HC Wainwright & Co. Initiates Coverage Of Biohaven (BHVN) …

1 week from now

Fintel reports that on December 22, 2023, HC Wainwright & Co. initiated coverage of Biohaven (NYSE:BHVN) with a Buy recommendation. Analyst Price Forecast Suggests 5.47% Downside …

msn.com

$59.00
OFF

H.C. Wainwright Reiterates Buy Rating On Biohaven Pharmaceutical ...

1 week from now

Sep 24, 2024 · H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating and $59.00 price target on Biohaven Pharmaceutical Holding (NYSE: BHVN).The analyst commented: "In what …

streetinsider.com

$55.00
OFF

Biohaven’s (BHVN) Overweight Rating Reiterated At Cantor …

1 week from now

Oct 26, 2024 · Leerink Partners boosted their price objective on shares of Biohaven from $55.00 to $60.00 and gave the company an “outperform” rating in a research report on Monday, …

americanbankingnews.com

$12
OFF

BHVN Stock: What's Next For Biohaven After A $12 Billion Buyout ...

1 week from now

Feb 2, 2023 · Biohaven (BHVN) is following the same strategy with its remaining drug pipeline as it did prior to Pfizer 's (PFE) massive buyout of the bulk of its assets — and BHVN stock has …

investors.com

$66.00
OFF

Biohaven's (BHVN) "Overweight" Rating Reiterated At Cantor …

1 week from now

Oct 23, 2024 · Get Biohaven alerts: BHVN has been the subject of several other reports. Piper Sandler upped their target price on Biohaven from $66.00 to $76.00 and gave the company an …

marketbeat.com

FAQs about HC Wainwright & Co. Initiates Coverage of Biohaven (BHVN) with … Coupon?

Will HC Wainwright & Co buy Biohaven (bhvn)?

Fintel reports that on December 22, 2023, HC Wainwright & Co. initiated coverage of Biohaven (NYSE:BHVN) with a Buy recommendation. ...

Should you buy Biohaven Ltd (bhvn)?

Biohaven Ltd. (BHVN) H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Biohaven Ltd. today and set a price target of $59.00. The company’s shares closed last Monday at $45.94. According to TipRanks.com, Tsao is a 5-star analyst with an average return of 11.6% and a 45.7% success rate. ...

Is Biohaven a good stock to buy?

Biohaven Ltd. has an analyst consensus of Strong Buy, with a price target consensus of $59.09, a 27.1% upside from current levels. In a report issued on September 16, Jefferies also initiated coverage with a Buy rating on the stock with a $57.00 price target. ...

How many funds own Biohaven (bhvn)?

There are 422 funds or institutions reporting positions in Biohaven. This is an increase of 25 owner (s) or 6.30% in the last quarter. Average portfolio weight of all funds dedicated to BHVN is 0.39%, an increase of 15.04%. Total shares owned by institutions increased in the last three months by 8.45% to 73,595K shares. ...

What is the average one-year price target for Biohaven?

As of December 18, 2023, the average one-year price target for Biohaven is 37.89. The forecasts range from a low of 31.31 to a high of $60.90. The average price target represents a decrease of 5.47% from its latest reported closing price of 40.08. See our leaderboard of companies with the largest price target upside. ...

Does Biohaven pharmaceutical holding company stock change in the last quarter?

No change in the last quarter. (This description is provided by the company.) Biohaven Pharmaceutical Holding Company Ltd. is a commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-class therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. ...